🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

West China Second University Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with West China Second University Hospital as lead sponsor. Synced 26 Sep 2026
15Current trials
7Recruiting now
8Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

West China Second University Hospital is the lead sponsor of 15 current clinical trials in our China register. 7 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Luvometinib, Cadonilimab and Dabrafenib. The most-studied condition is Langerhans Cell Histiocytosis (LCH).

ClinicalTrials.gov trials by status

  • Recruiting747%
  • Not yet open320%
  • Active, closed17%
  • By invitation427%

Trials by phase

  • Observational747%
  • Not applicable533%
  • Phase 2213%
  • Phase 2/317%
01

Clinical trials sponsored by West China Second University Hospital

15 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis
NCT07431060 · ClinicalTrials.gov ↗ · Langerhans Cell Histiocytosis (LCH)
Not applicable Recruiting 2026-02 China
A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab(AK104) for Newly Diagnosed Local Advanced Cervical Cancer
NCT06251388 · ClinicalTrials.gov ↗ · Cervical Cancer
Phase 2 Recruiting 2024-02 China
Cardiac Magnetic Resonance Monitoring of Immune Checkpoint Inhibitor-related Cardiotoxicity
NCT06132984 · ClinicalTrials.gov ↗ · Immune Checkpoint Inhibitors, Cardiotoxicity
Observational Recruiting 2023-11 China
Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children
NCT07022834 · ClinicalTrials.gov ↗ · Langerhans Cell Histiocytosis (LCH)
Phase 2 Recruiting 2025-06 China
Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions
NCT07371182 · ClinicalTrials.gov ↗ · Langerhans Cell Histiocytosis (LCH)
Not applicable Recruiting 2026-06 China
Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia
NCT06881056 · ClinicalTrials.gov ↗ · Respiratory Syncytial Virus (RSV)
Not applicable Recruiting 2024-07 China
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
NCT03463252 · ClinicalTrials.gov ↗ · Endometrial Cancer, Atypical Endometrial Hyperplasia
Drug: GnRH-a
Phase 2/3 Recruiting 2018-04 China
Comparing the Efficacy of TU-LESS and vNOTES for Hysterectomy of Enlarged Uterus
NCT06663553 · ClinicalTrials.gov ↗ · Enlarged Uterus, Adenomyosis, Uterine Fibroids (UF)
Not applicable Not yet open 2025-10 China
A Multicenter Cohort Study of Duchenne and Becker Muscular Dystrophy in Western Chinese Children
NCT07511920 · ClinicalTrials.gov ↗ · Muscular Dystrophy, Becker, Muscular Dystrophy, Muscular Dystrophy (DMD)
Observational Not yet open 2026-04 China
Exploring Gut Microbiome Differences in Female Cancer Patients With Varied Ovarian Function and Fertility Outcomes Following Immune Checkpoint Inhibitor Therapy
NCT07201259 · ClinicalTrials.gov ↗ · Malignant Tumors
Observational Not yet open 2025-10 China
A Integrated Study in Pediatric Patients with Cardiomyopathy
NCT06641830 · ClinicalTrials.gov ↗ · Pediatric Cardiomyopathy
Observational By invitation 2024-09 China
The Value of Cardiovascular Imaging in Kawasaki Disease
NCT06641817 · ClinicalTrials.gov ↗ · Kawasaki Disease
Observational By invitation 2023-09 China
Magnetic Resonance Myocardial Stress Perfusion in Pediatric Patients with Cardiovascular Disease
NCT06641843 · ClinicalTrials.gov ↗ · Kawasaki Disease, Cardiovascular Disease, Anomalous Origin of Coronary Artery
Observational By invitation 2024-09 China
Cardiovascular Imaging in Pediatric Myocarditis
NCT06652399 · ClinicalTrials.gov ↗ · Myocarditis
Observational By invitation 2023-11 China
Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids
NCT06244251 · ClinicalTrials.gov ↗ · Uterine Fibroid, Uterine Sarcoma, Uterine Leiomyosarcoma
Not applicable Active, closed 2023-06 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in West China Second University Hospital trials

8 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in West China Second University Hospital trials

22 conditions
Langerhans Cell Histiocytosis (LCH)3Kawasaki Disease2Enlarged Uterus1Adenomyosis1Uterine Fibroids (UF)1Pediatric Cardiomyopathy1Uterine Fibroid1Uterine Sarcoma1Uterine Leiomyosarcoma1Muscular Dystrophy, Becker1Muscular Dystrophy1Muscular Dystrophy (DMD)1Muscular Dystrophy, Duchenne1Cervical Cancer1Immune Checkpoint Inhibitors, Cardiotoxicity1Cardiovascular Disease1Anomalous Origin of Coronary Artery1Respiratory Syncytial Virus (RSV)1Endometrial Cancer1Atypical Endometrial Hyperplasia1Myocarditis1Malignant Tumors1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China157

A trial with sites in more than one country appears in each of those registers.

05

Questions about West China Second University Hospital trials

How many clinical trials does West China Second University Hospital sponsor?

West China Second University Hospital is the lead sponsor of 15 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are West China Second University Hospital trials recruiting?

Yes. 7 of its 15 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is West China Second University Hospital testing?

Its current trials name 8 drugs and biologicals as interventions. The most frequent are Luvometinib (2), Cadonilimab (1), Dabrafenib (1), GnRH-a (1) and Mercaptopurine (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.